Company / Net Debt per Share
SUTRO BIOPHARMA, INC. Net Debt per Share History
FY2018-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Debt per Share
-$0.31
FY2022
5-year range
-$3.96 / -$0.31
FY2018-FY2022
Trend
+92.3%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $0.85 to $-0.31 over the past 2 years.
Based on SEC 10-K filings.
-0.31 in FY2022.
Improved from $0.85 to $-0.31 over the past 2 years.
Net Debt per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2022, net debt per share increased 92.3% year-over-year.
- Peak net debt per share was recorded in FY2020.
- Lowest net debt per share in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score -3.45 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net Debt per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | -$0.31 | +92.3% |
| FY2021 | -$3.96 | -566.7% |
| FY2020 | $0.85 | +116.6% |
| FY2019 | -$5.10 | +80.3% |
| FY2018 | -$25.83 | - |
As of FY2022 · SEC 10-K · Updated Jun 28, 2026